2020
Adherence to study drug in a stroke prevention trial"?>
Kiran A, Viscoli CM, Furie KL, Gorman M, Kernan WN. Adherence to study drug in a stroke prevention trial"?>. Journal Of Stroke And Cerebrovascular Diseases 2020, 29: 105048. PMID: 32912514, PMCID: PMC7487071, DOI: 10.1016/j.jstrokecerebrovasdis.2020.105048.Peer-Reviewed Original ResearchConceptsRate of discontinuationStudy drugDrug holidayTreatment groupsActive study drugAdverse effectsInsulin Resistance InterventionPremature drug discontinuationRecent ischemic strokeStroke Prevention TrialDouble-blind trialTransient ischemic attackClinical trial researchPhases of adherenceDrug discontinuationIschemic attackStroke preventionDiscontinuation ratesIschemic strokeActive therapyMedical therapyPatient adherencePrevention trialsStroke trialsPharmacodynamic effects
1989
Ceftriaxone Compared with Cefotaxime for Serious Bacterial Infections
Smith C, Petty B, Hendrix C, Kernan W, Garver P, Fox K, Beamer A, Carbone K, Threlkeld M, Lietman P. Ceftriaxone Compared with Cefotaxime for Serious Bacterial Infections. The Journal Of Infectious Diseases 1989, 160: 442-447. PMID: 2668428, DOI: 10.1093/infdis/160.3.442.Peer-Reviewed Original ResearchMeSH KeywordsAdultBacteriaBacterial InfectionsCefotaximeCeftriaxoneClinical Trials as TopicDrug Administration ScheduleFemaleHumansMaleMiddle AgedConceptsSerious bacterial infectionsBacterial infectionsDouble-blind clinical trialSuspected serious bacterial infectionResponse rateCefotaxime 2 gCeftriaxone 2 gDose of ceftriaxoneTreatment groupsDose of cefotaximeFrequency of diarrheaClinical responseAnaerobic infectionsProthrombin timeCeftriaxoneClinical trialsCefotaximeInfecting organismInfectionAdverse effectsDoseTreatmentDaysThrombophlebitisProthrombin